Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
serplulimab + HANBEITAI
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Serplulimab + HANBEITAI is a monoclonal antibody combination therapy developed by Shanghai Henlius Biotech. It consists of serplulimab (brand name: HANSIZHUANG), a recombinant humanized anti-PD-1 monoclonal antibody, and HANBEITAI, a biosimilar of bevacizumab that targets vascular endothelial growth factor (VEGF). This combination is designed to provide synergistic antitumor activity by simultaneously blocking the PD-1/PD-L1 immune checkpoint pathway to restore T-cell mediated immune responses and inhibiting VEGF-driven angiogenesis to normalize tumor vasculature. By addressing both immune evasion and pathological angiogenesis, the regimen aims to improve therapeutic outcomes in advanced solid tumors. It is currently being evaluated in Phase 3 clinical trials for the first-line treatment of non-squamous non-small cell lung cancer (nsNSCLC) and in Phase 2 trials for unresectable or metastatic hepatocellular carcinoma (HCC) and colorectal cancer (CRC).
- Brand names
- HANSIZHUANG + HANBEITAI
- Other names
- serplulimab + HLX04serplulimab + bevacizumab biosimilarHetronifly + HANBEITAIHLX10 + HLX04
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on serplulimab + HANBEITAI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on serplulimab + HANBEITAI.